Scientific

MK5 Microarray Data

Affected Genes - Ontology Breakdown - Gene Enrichment - Proteome Analysis

These are the micro-array results of a differential gene expression microarray experiments and the subsequent analysis steps performed on them. The up/down- regulation ratio was obtained by measuring WT cells against MK5 activated cells. See material and methods for technical information as well as the data usage policy.

MK5 Proteome Analysis

Table 3: Type II network, divided ranks. This table presents the output of the simulation of a type-II network in which we relied on the high confidence interactions and micro-array results. The output of the micro-array was then ranked and these ranks used as input into the network simulation. After performing two such simulations (one for the MK5 off and one for the MK5 on microarray output), we divided the ranks and sorted the results accordingly. The output of this technique is a collection of proteins that cluster naturally together.


Navigation/Query Panel:
Click on the attribute name to hide/unhide it. The green arrows can be used to shift columns left/right. Exact word match is written as =..., regular expressions can be matched with ~.... To select all values larger or equal than use >.... This would be <... for values smaller or equal than. To select all values within a specific range use [...,...].
Rank Gene description Value Type Network Comparison Type Interaction Map Filtered red green network_comparison
Results: HTML CSV LaTeX Showing element 2013 to 2062 of 3228 in total 
Value Type: Ranked
Network Comparison Type: Divided
Interaction Map: High confidence
Filtered: 1

\def\wcA{0.16666666666667\textwidth}
\def\wcB{0.16666666666667\textwidth}
\def\wcC{0.16666666666667\textwidth}
\def\wcD{0.16666666666667\textwidth}
\def\wcE{0.16666666666667\textwidth}
\begin{longtable}{|c|c|c|c|c|}
\hline
\parbox{\wcA}{\vspace{3pt}\noindent
Rank\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
description\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
red\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
green\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
network\_comparison\vspace{3pt}}\\
\hline
\hline
\parbox{\wcA}{\vspace{3pt}\noindent
2013\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
protein phosphatase 1, regulatory (inhibitor) subunit 12b isoform a; myosin phosphatase regulatory subunit; myosin phosphatase, target subunit 2. [source:refseq;acc:nm\_002481]\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
217.662\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
215.693\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
1.00913\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
2014\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
protein phosphatase 1, regulatory (inhibitor) subunit 12a; myosin phosphatase, target subunit 1. [source:refseq;acc:nm\_002480]\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
217.676\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
215.709\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
1.00912\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
2015\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
dna topoisomerase iii alpha (ec 5.99.1.2). [source:swissprot;acc:q13472]\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
217.941\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
215.979\vspace{3pt}}&\multirow{2}{*}{\parbox{\wcE}{\vspace{3pt}\noindent
1.00908\vspace{3pt}}}\\\cline{1-4}
\parbox{\wcA}{\vspace{3pt}\noindent
2016\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
electron transfer flavoprotein-ubiquinone oxidoreductase, mitochondrial precursor (ec 1.5.5.1) (etf-qo) (etf-ubiquinone oxidoreductase) (etf dehydrogenase) (electron-transferring- flavoprotein dehydrogenase). [source:swissprot;acc:q16134]\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
199.092\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
197.301\vspace{3pt}}&\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
2017\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
ribosome biogenesis regulatory protein homolog. [source:swissprot;acc:q15050]\vspace{3pt}}&\multirow{2}{*}{\parbox{\wcC}{\vspace{3pt}\noindent
127.397\vspace{3pt}}}&\multirow{2}{*}{\parbox{\wcD}{\vspace{3pt}\noindent
128.553\vspace{3pt}}}&\multirow{2}{*}{\parbox{\wcE}{\vspace{3pt}\noindent
1.00907\vspace{3pt}}}\\\cline{1-2}
\parbox{\wcA}{\vspace{3pt}\noindent
2018\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
serine/threonine protein phosphatase pp1-alpha 1 catalytic subunit (ec 3.1.3.16) (pp-1a). [source:swissprot;acc:p08129]\vspace{3pt}}&&&\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
2019\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
acyl-coa dehydrogenase, short/branched chain specific, mitochondrial precursor (ec 1.3.99.-) (sbcad) (2-methyl branched chain acyl-coa dehydrogenase) (2-mebcad) (2-methylbutyryl-coenzyme a dehydrogenase) (2-methylbutyryl-coa dehydrogenase). [source:swissprot;acc:p45954]\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
215.799\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
213.865\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
1.00904\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
2020\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
putative eukaryotic translation initiation factor 3 subunit (eif-3) (fragment). [source:swissprot;acc:o75153]\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
223.168\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
221.176\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
1.00901\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
2021\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
hexaprenyldihydroxybenzoate methyltransferase, mitochondrial precursor (ec 2.1.1.114) (dihydroxyhexaprenylbenzoate methyltransferase) (3,4- dihydroxy-5-hexaprenylbenzoate methyltransferase) (dhhb methyltransferase) (dhhb-mt) (dhhb-mtase). [source:swissprot;acc:q9nzj6]\vspace{3pt}}&\multirow{3}{*}{\parbox{\wcC}{\vspace{3pt}\noindent
208.601\vspace{3pt}}}&\multirow{3}{*}{\parbox{\wcD}{\vspace{3pt}\noindent
210.464\vspace{3pt}}}&\multirow{3}{*}{\parbox{\wcE}{\vspace{3pt}\noindent
1.00893\vspace{3pt}}}\\\cline{1-2}
\parbox{\wcA}{\vspace{3pt}\noindent
2022\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
atp synthase coupling factor b, mitochondrial precursor. [source:swissprot;acc:q99766]\vspace{3pt}}&&&\\\cline{1-2}
\parbox{\wcA}{\vspace{3pt}\noindent
2023\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
guanine deaminase (ec 3.5.4.3) (guanase) (guanine aminase) (guanine aminohydrolase) (gah) (p51-nedasin). [source:swissprot;acc:q9y2t3]\vspace{3pt}}&&&\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
2024\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
vacuolar protein sorting 33b (hvps33b). [source:swissprot;acc:q9h267]\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
215.553\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
213.663\vspace{3pt}}&\multirow{5}{*}{\parbox{\wcE}{\vspace{3pt}\noindent
1.00885\vspace{3pt}}}\\\cline{1-4}
\parbox{\wcA}{\vspace{3pt}\noindent
2025\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
alanine aminotransferase (ec 2.6.1.2) (glutamic--pyruvic transaminase) (gpt) (glutamic--alanine transaminase). [source:swissprot;acc:p24298]\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
189.987\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
191.668\vspace{3pt}}&\\\cline{1-4}
\parbox{\wcA}{\vspace{3pt}\noindent
2026\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
vacuolar protein sorting 11 (hvps11) (pp3476). [source:swissprot;acc:q9h270]\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
215.553\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
213.663\vspace{3pt}}&\\\cline{1-4}
\parbox{\wcA}{\vspace{3pt}\noindent
2027\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
lin-7 homolog c; lin-7 protein 3. [source:refseq;acc:nm\_018362]\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
225.015\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
223.041\vspace{3pt}}&\\\cline{1-4}
\parbox{\wcA}{\vspace{3pt}\noindent
2028\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
vacuolar protein sorting 33a (hvps33a). [source:swissprot;acc:q96ax1]\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
215.553\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
213.663\vspace{3pt}}&\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
2029\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
cytoplasmic cysteine conjugate-beta lyase; glutamine-phenylpyruvate aminotransferase. [source:refseq;acc:nm\_004059]\vspace{3pt}}&\multirow{2}{*}{\parbox{\wcC}{\vspace{3pt}\noindent
189.999\vspace{3pt}}}&\multirow{2}{*}{\parbox{\wcD}{\vspace{3pt}\noindent
191.677\vspace{3pt}}}&\multirow{2}{*}{\parbox{\wcE}{\vspace{3pt}\noindent
1.00883\vspace{3pt}}}\\\cline{1-2}
\parbox{\wcA}{\vspace{3pt}\noindent
2030\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
alanine aminotransferase 2; glutamic-pyruvate transaminase 2. [source:refseq;acc:nm\_133443]\vspace{3pt}}&&&\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
2031\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
traf and tnf receptor-associated protein; ets1-associated protein 2. [source:refseq;acc:nm\_016614]\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
218.466\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
216.562\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
1.00879\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
2032\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
f-actin capping protein alpha-3 subunit (capz alpha-3) (germ cell- specific protein 3). [source:swissprot;acc:q96kx2]\vspace{3pt}}&\multirow{2}{*}{\parbox{\wcC}{\vspace{3pt}\noindent
215.322\vspace{3pt}}}&\multirow{2}{*}{\parbox{\wcD}{\vspace{3pt}\noindent
213.46\vspace{3pt}}}&\multirow{2}{*}{\parbox{\wcE}{\vspace{3pt}\noindent
1.00872\vspace{3pt}}}\\\cline{1-2}
\parbox{\wcA}{\vspace{3pt}\noindent
2033\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
f-actin capping protein beta subunit (capz beta). [source:swissprot;acc:p47756]\vspace{3pt}}&&&\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
2034\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
centaurin beta 5 (cnt-b5). [source:swissprot;acc:q96p50]\vspace{3pt}}&\multirow{4}{*}{\parbox{\wcC}{\vspace{3pt}\noindent
218.919\vspace{3pt}}}&\multirow{2}{*}{\parbox{\wcD}{\vspace{3pt}\noindent
220.812\vspace{3pt}}}&\multirow{4}{*}{\parbox{\wcE}{\vspace{3pt}\noindent
1.00865\vspace{3pt}}}\\\cline{1-2}
\parbox{\wcA}{\vspace{3pt}\noindent
2035\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
centaurin beta 2 (cnt-b2). [source:swissprot;acc:q15057]\vspace{3pt}}&&&\\\cline{1-2}\cline{4-4}
\parbox{\wcA}{\vspace{3pt}\noindent
2036\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
lamin b1. [source:swissprot;acc:p20700]\vspace{3pt}}&&\parbox{\wcD}{\vspace{3pt}\noindent
220.813\vspace{3pt}}&\\\cline{1-2}\cline{4-4}
\parbox{\wcA}{\vspace{3pt}\noindent
2037\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
centaurin beta 1 (cnt-b1). [source:swissprot;acc:q15027]\vspace{3pt}}&&\parbox{\wcD}{\vspace{3pt}\noindent
220.812\vspace{3pt}}&\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
2038\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
lamin a/c (70 kda lamin). [source:swissprot;acc:p02545]\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
218.92\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
220.811\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
1.00864\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
2039\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
acetyl-coenzyme a synthetase, cytoplasmic (ec 6.2.1.1) (acetate--coa ligase) (acyl-activating enzyme) (acetyl-coa synthetase) (acs) (acecs). [source:swissprot;acc:q9nr19]\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
190.551\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
192.191\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
1.00861\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
2040\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
brachyury protein (t protein). [source:swissprot;acc:o15178]\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
210.586\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
208.803\vspace{3pt}}&\multirow{3}{*}{\parbox{\wcE}{\vspace{3pt}\noindent
1.00854\vspace{3pt}}}\\\cline{1-4}
\parbox{\wcA}{\vspace{3pt}\noindent
2041\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
ataxin-1 ubiquitin-like interacting protein. [source:refseq;acc:nm\_020131]\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
196.808\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
195.141\vspace{3pt}}&\\\cline{1-4}
\parbox{\wcA}{\vspace{3pt}\noindent
2042\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
t-box transcription factor tbx19 (t-box protein 19). [source:swissprot;acc:o60806]\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
210.586\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
208.803\vspace{3pt}}&\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
2043\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
ubiquilin 1 isoform 1. [source:refseq;acc:nm\_013438]\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
196.837\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
195.173\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
1.00853\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
2044\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
adapter-related protein complex 3 beta 1 subunit (beta-adaptin 3a) (ap-3 complex beta-3a subunit) (beta-3a-adaptin). [source:swissprot;acc:o00203]\vspace{3pt}}&\multirow{3}{*}{\parbox{\wcC}{\vspace{3pt}\noindent
199.928\vspace{3pt}}}&\multirow{3}{*}{\parbox{\wcD}{\vspace{3pt}\noindent
198.24\vspace{3pt}}}&\multirow{3}{*}{\parbox{\wcE}{\vspace{3pt}\noindent
1.00851\vspace{3pt}}}\\\cline{1-2}
\parbox{\wcA}{\vspace{3pt}\noindent
2045\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
ny-ren-24 antigen (fragment). [source:sptrembl;acc:q9y5a4]\vspace{3pt}}&&&\\\cline{1-2}
\parbox{\wcA}{\vspace{3pt}\noindent
2046\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
adapter-related protein complex 3 beta 2 subunit (beta-adaptin 3b) (ap-3 complex beta-3b subunit) (beta-3b-adaptin) (neuron-specific vesicle coat protein beta-nap). [source:swissprot;acc:q13367]\vspace{3pt}}&&&\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
2047\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
solute carrier family 2, facilitated glucose transporter, member 6 (glucose transporter type 6) (glucose transporter type 9). [source:swissprot;acc:q9ugq3]\vspace{3pt}}&\multirow{2}{*}{\parbox{\wcC}{\vspace{3pt}\noindent
224.124\vspace{3pt}}}&\multirow{2}{*}{\parbox{\wcD}{\vspace{3pt}\noindent
226.003\vspace{3pt}}}&\multirow{2}{*}{\parbox{\wcE}{\vspace{3pt}\noindent
1.00838\vspace{3pt}}}\\\cline{1-2}
\parbox{\wcA}{\vspace{3pt}\noindent
2048\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
solute carrier family 2, facilitated glucose transporter, member 8 (glucose transporter type 8) (glucose transporter type x1). [source:swissprot;acc:q9ny64]\vspace{3pt}}&&&\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
2049\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
translation initiation factor eif-2b beta subunit (eif-2b gdp-gtp exchange factor) (s20i15) (s20iii15). [source:swissprot;acc:p49770]\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
220.787\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
222.634\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
1.00837\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
2050\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
sh3 domain-binding glutamic acid-rich protein (sh3bgr protein) (21- glutamic acid-rich protein) (21-garp). [source:swissprot;acc:p55822]\vspace{3pt}}&\multirow{2}{*}{\parbox{\wcC}{\vspace{3pt}\noindent
218.79\vspace{3pt}}}&\multirow{2}{*}{\parbox{\wcD}{\vspace{3pt}\noindent
216.981\vspace{3pt}}}&\multirow{13}{*}{\parbox{\wcE}{\vspace{3pt}\noindent
1.00834\vspace{3pt}}}\\\cline{1-2}
\parbox{\wcA}{\vspace{3pt}\noindent
2051\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
oxidation resistance 1. [source:refseq;acc:nm\_181354]\vspace{3pt}}&&&\\\cline{1-4}
\parbox{\wcA}{\vspace{3pt}\noindent
2052\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
ornithine decarboxylase antizyme inhibitor. [source:swissprot;acc:o14977]\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
207.667\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
205.95\vspace{3pt}}&\\\cline{1-4}
\parbox{\wcA}{\vspace{3pt}\noindent
2053\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
lats, large tumor suppressor, homolog 2; lats (large tumor suppressor, drosophila) homolog 2. [source:refseq;acc:nm\_014572]\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
218.79\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
216.981\vspace{3pt}}&\\\cline{1-4}
\parbox{\wcA}{\vspace{3pt}\noindent
2054\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
ornithine decarboxylase-like protein (ec 4.1.1.17) (odc-paralogue) (odc-p). [source:swissprot;acc:q96a70]\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
207.665\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
205.948\vspace{3pt}}&\\\cline{1-4}
\parbox{\wcA}{\vspace{3pt}\noindent
2055\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
dymeclin. [source:refseq;acc:nm\_017653]\vspace{3pt}}&\multirow{8}{*}{\parbox{\wcC}{\vspace{3pt}\noindent
218.79\vspace{3pt}}}&\multirow{8}{*}{\parbox{\wcD}{\vspace{3pt}\noindent
216.981\vspace{3pt}}}&\\\cline{1-2}
\parbox{\wcA}{\vspace{3pt}\noindent
2056\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
sh3 domain-binding glutamic acid-rich-like protein. [source:swissprot;acc:o75368]\vspace{3pt}}&&&\\\cline{1-2}
\parbox{\wcA}{\vspace{3pt}\noindent
2057\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
lats homolog 1. [source:refseq;acc:nm\_004690]\vspace{3pt}}&&&\\\cline{1-2}
\parbox{\wcA}{\vspace{3pt}\noindent
2058\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
sh3 domain-binding glutamic acid-rich-like protein 2 (fovea-associated sh3 domain binding protein). [source:swissprot;acc:q9ujc5]\vspace{3pt}}&&&\\\cline{1-2}
\parbox{\wcA}{\vspace{3pt}\noindent
2059\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
nuclear receptor coactivator 7; estrogen receptor associated protein 140 kda. [source:refseq;acc:nm\_181782]\vspace{3pt}}&&&\\\cline{1-2}
\parbox{\wcA}{\vspace{3pt}\noindent
2060\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
dj132f21.2 (contains a novel protein similar to the l82e from drosophila) (fragment). [source:sptrembl;acc:q9h125]\vspace{3pt}}&&&\\\cline{1-2}
\parbox{\wcA}{\vspace{3pt}\noindent
2061\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
tbc1 domain family protein c22orf4-like (fragment). [source:swissprot;acc:q9nu19]\vspace{3pt}}&&&\\\cline{1-2}
\parbox{\wcA}{\vspace{3pt}\noindent
2062\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
tbc1 domain family protein c22orf4. [source:swissprot;acc:q8wua7]\vspace{3pt}}&&&\\\hline
nd{longtable}

Legend:
- Rank is the rank after comparing the two networks

 - Gene is the ensembl human gene identifier measured by 1 or more probes on the microarray

 - Value Type describes how the microarray measurement was processed. Ranked indicates that we sorted all measurements and use the rank as red and green value. Measured is the normal measurement. Squared and Rooted are the square and square root respecitcely. This might be valueable to compensate for non linear light distributions.

 - Network Comparison Type describes whether we divided the red and green types or whether we sutractcted them

 - Interaction Map specifies whether we used only the hig hconfidence protein-protein interactions or also included the low confidence interactions.

 - Filtered specifies whether we only included the high confidence microarry measurements or not.
- http://analysis.yellowcouch.org/